Humana
HUM
$407.02
-0.68%
Humana Inc. is one of the largest private health insurers in the United States, operating a business built almost entirely around government-sponsored healthcare programs — Medicare Advantage, Medicaid, and the military's Tricare program — supplemented by a growing healthcare services arm that includes primary care, at-home care, and pharmacy benefit management through its CenterWell segment. The company occupies a distinct niche within managed care: rather than competing broadly across commercial insurance like UnitedHealth or CVS, Humana is the purest large-cap play on Medicare Advantage demographics, giving it both a structural tailwind from aging baby boomers and concentrated exposure to government reimbursement policy. The current investor narrative is dominated by a dramatic turnaround: after a brutal 2024-2025 period marked by elevated medical cost trends and a Q4 2025 loss of $796 million, Humana has returned to profitability with Q1 2026 net income of $1.186 billion, and the stock has responded with a 147.7% six-month gain. Sentiment has been further boosted by a larger-than-expected 2027 Medicare Advantage rate increase from CMS, which lifted the entire managed care sector, while speculation about M&A activity (including reported interest in MaxHealth) and a Wells Fargo upgrade to Overweight in July 2026 have added fuel to the recovery story.…
HUM
Humana
$407.02
Related headlines
Investment Opinion: Should I buy HUM Today?
The synthesized recommendation is Hold, with a bias toward Buy on pullbacks. The core thesis is that Humana's Q1 2026 earnings recovery and favorable CMS rate environment provide a solid foundation, but the stock's 147.7% six-month rally has already priced in much of the good news, leaving limited margin of safety. The analyst consensus rating of 2.19 (Buy) and average target price of $418.61 imply only 2.1% upside from the current $409.80, suggesting the stock is fairly valued near-term.
Supporting evidence includes the 23.47% year-over-year revenue growth in Q1 2026, the swing to $1.186 billion in net income, and a forward P/E of 24.73 that is reasonable if earnings estimates of $35.78 are met. The price-to-sales ratio of 0.24 and EV/sales of 0.27 are attractive for a company with $205.8 billion in estimated revenue, and the 1.39% dividend yield offers modest income. However, the net margin of 0.92% and debt-to-equity of 0.73 highlight the fragility of the recovery.
The biggest risks that could invalidate the thesis are a re-acceleration of medical costs, adverse regulatory changes to Medicare Advantage, and integration challenges from M&A. The rating would upgrade to Buy if the stock pulls back to the $350-$370 range (implied by a forward P/E below 22x) or if Q2 2026 earnings show margin expansion above 2%. It would downgrade to Sell if revenue growth decelerates below 10% or if medical cost trends push the company back to a quarterly loss. Relative to its history and peers, HUM appears fairly valued after the massive run, with the market pricing in a successful turnaround.
Sign up to view all
HUM 12-Month Price Forecast
Humana's investment case is balanced after a massive rally. The company has proven it can return to profitability, but the stock now trades near analyst targets, limiting upside. The key driver will be whether Q2 2026 results confirm sustainable margin expansion; if so, the stock could reach the bull case. Conversely, any sign of cost inflation could trigger a sharp correction toward the bear case. With a beta of 0.745 and a 1.39% dividend yield, HUM offers defensive characteristics but limited near-term catalysts. I would upgrade to bullish if the stock pulls back to $370 or if Q2 EPS exceeds $10.50; I would downgrade to bearish if medical cost trends worsen or if membership declines.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $419.04 and implied upside of +3.0% versus the current price.
Average Target
$419.04
0 analysts
Implied Upside
+3.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$280 - $513
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: HUM Investment Factors
The bull case currently has stronger evidence, driven by the dramatic Q1 2026 earnings turnaround, massive relative strength, and a favorable CMS rate environment. However, the bear case is not without merit: razor-thin margins, regulatory concentration, and a leveraged balance sheet mean that any misstep could quickly reverse the recovery. The single most important tension is whether Humana can sustain its margin recovery amid persistent medical cost trends; if Q2 2026 results show margin expansion, the bull case strengthens considerably, but any sign of cost re-acceleration could trigger a sharp sell-off given the stock's rapid ascent.
Bullish
- Explosive Q1 2026 earnings turnaround: Humana swung from a Q4 2025 net loss of $796 million (EPS -$6.61) to Q1 2026 net income of $1.186 billion (EPS $9.85), a massive sequential recovery. Revenue grew 23.47% year-over-year to $39.648 billion, demonstrating both top-line momentum and restored profitability.
- Massive relative strength vs. market: HUM has gained 147.7% over the past six months and 47.0% over the past year, crushing the S&P 500's 15.4% and 16.2% respective returns. The relative strength over six months is a staggering 132.3 percentage points, indicating powerful institutional accumulation.
- Analyst consensus upside remains: With 23 analysts covering the stock, the average price target of $418.61 implies roughly 2.1% upside from the current $409.80, while the high target of $513.00 suggests 25.2% potential. The consensus recommendation is 'buy' with a mean rating of 2.19.
- CMS rate hike boosts revenue visibility: A larger-than-expected 2027 Medicare Advantage payment increase from CMS has improved revenue visibility and sentiment across the managed care sector. This directly benefits Humana, which derives nearly all membership from government programs, and reduces policy uncertainty.
Bearish
- Extremely thin margins leave no cushion: Net margin is just 0.92%, operating margin 1.12%, and gross margin 14.54%. A mere 1% increase in medical costs could wipe out profits entirely, as evidenced by the Q4 2025 loss. The business remains highly vulnerable to medical cost inflation.
- Earnings volatility and negative PEG: The trailing EPS of $0.04 and negative PEG ratio of -18.55 reflect the recent loss cycle. Quarterly EPS has swung from -$6.61 to $9.85 in just two quarters, highlighting unpredictable earnings that complicate valuation and forecasting.
- Regulatory concentration risk: Nearly all membership stems from Medicare, Medicaid, and Tricare, making Humana the most policy-sensitive large-cap insurer. Any adverse change to Medicare Advantage reimbursement, risk-adjustment coding, or Star Ratings could severely impact revenue and margins.
- High debt and weak liquidity: Debt-to-equity of 0.73 and a current ratio of only 0.72 indicate a leveraged balance sheet with limited short-term liquidity. Interest expense of $193 million in Q1 2026 consumes a meaningful portion of operating income.
HUM Technical Analysis
Beta
0.74
0.74x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$429
Price range past year
Annual Return
+47.2%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +4.6% | -2.0% |
| 3m | +10.2% | +1.4% |
| 6m | +138.8% | +15.0% |
| 1y | +47.2% | +15.7% |
| ytd | +53.9% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Quarterly Revenue
$39.6B
2026-03
Revenue YoY Growth
+23.5%
YoY Comparison
Gross Margin
15.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant given Humana's razor-thin margins and leveraged balance sheet. Net margin stands at just 0.92%, operating margin at 1.12%, and gross margin at 14.54%, leaving virtually no buffer against unexpected medical cost increases. The company's debt-to-equity ratio of 0.73 and current ratio of 0.72 indicate limited financial flexibility, while interest expense of $193 million in Q1 2026 consumes a notable share of operating income. Additionally, the Q4 2025 net loss of $796 million demonstrates how quickly profitability can evaporate when medical costs rise.
Market and competitive risks are amplified by Humana's concentrated exposure to government programs and its premium valuation relative to history. The stock trades at a trailing P/E of 25.95 and forward P/E of 24.73, which may be vulnerable to compression if growth slows. With a beta of 0.745, Humana is less volatile than the broader market, but sector rotation away from managed care or adverse regulatory news could still pressure shares. Recent news highlights CMS's 2027 Medicare Advantage rate increase as a positive, but any future policy changes or competitive threats from larger rivals like UnitedHealth and CVS could erode Humana's niche advantage.
The worst-case scenario would involve a combination of resurgent medical cost inflation, unfavorable regulatory changes, and a failure to integrate acquisitions like MaxHealth. In such a scenario, the stock could retest its 52-week low of $163.11, representing a 60.2% decline from the current price of $409.80. The analyst low target of $280.00 implies a 31.7% downside, while the maximum drawdown over the past year was -47.54%. Investors could lose between 32% and 60% of their capital if the turnaround stalls and sentiment reverses.
FAQ
The most severe risk is regulatory: Humana derives nearly all revenue from government programs, so any adverse change to Medicare Advantage reimbursement could be devastating. Financial risk is also high, with a debt-to-equity of 0.73 and a current ratio of 0.72, leaving little liquidity buffer. Operational risk stems from razor-thin margins (net margin 0.92%), where a 1% rise in medical costs could erase profits. Finally, competitive risk from larger, more diversified rivals like UnitedHealth and CVS could pressure membership and pricing. These risks are ranked from most to least severe.
Our 12-month forecast has three scenarios. The base case (55% probability) targets $400-$440, assuming EPS of $35.78 and revenue of $205.8 billion, with the stock trading around the analyst average of $418.61. The bull case (25%) targets $480-$513 if earnings exceed expectations and margins expand. The bear case (20%) targets $280-$320 if medical costs rise and regulatory headwinds emerge. The most likely scenario is the base case, hinging on Humana meeting its guidance and maintaining margin stability.
HUM's valuation is nuanced. The trailing P/E of 25.95 and forward P/E of 24.73 are above the broader market but reflect the company's unique Medicare Advantage focus. The price-to-sales ratio of 0.24 and EV/sales of 0.27 are exceptionally low, indicating the market is not paying a premium for revenue. However, the net margin of 0.92% means earnings are thin, so the P/E may overstate value. Compared to peers like UnitedHealth, HUM trades at a discount on sales but a premium on earnings. The market appears to be pricing in a successful turnaround, leaving little room for disappointment.
Humana presents a mixed risk/reward profile at the current price of $409.80. The stock has surged 147.7% over six months, and the analyst average target of $418.61 implies only 2.1% upside, suggesting limited near-term appreciation. However, the high target of $513.00 offers 25.2% potential if the turnaround accelerates. The biggest downside risk is a return to losses, which could send the stock toward the 52-week low of $163.11. For risk-tolerant investors with a long-term horizon, HUM could be a good buy on pullbacks, but at current levels, it is more of a Hold.
HUM is better suited for long-term investment, given its structural tailwind from aging demographics and the complexity of its turnaround. The stock's beta of 0.745 indicates lower volatility than the market, but its 47.5% max drawdown shows it can still be risky. The 1.39% dividend yield is modest but provides some income. Short-term trading is risky due to earnings volatility and regulatory news. A minimum holding period of 2-3 years is recommended to allow the Medicare Advantage story to fully play out and for margins to normalize.
